Metadata from OpenAlexLast checked: Sep 26, 2026

JID Innovations — Journal Profile & Submission Links

Elsevier BV · ISSN-L 2667-0267

Source-backed journal profile with OpenAlex metadata and links to official submission resources for JID Innovations.

This page provides a source-backed journal profile and links to official submission resources. Journal instructions can change. Always verify article types, formatting, fees, ethics requirements, and submission rules on the official journal website before submitting.

Official links

Publisher
Elsevier BV
Country
US
Open access
Yes
Listed in DOAJ
Yes
APC (USD)
—
Works count
489
Cited-by count
3601
OpenAlex 2-year mean citedness
2.15
Quartile
Q1

Catalog scope notes

Skin Science from Molecules to Population Health JID Innovations is an online-only Open Access journal that provides an international forum for the publication of high-quality, peer reviewed research in the field of skin biology and disease. JID Innovations features original scientific reports related to all aspects of skin science from molecular studies to population health, including studies addressing the pathogenesis and treatment of skin diseases. Submissions should address questions that are important and relevant to the community of researchers and clinicians focused on skin biology and disease. Submissions may confirm or challenge current knowledge, inform the community of a new technology or resource, advance a new hypothesis, or challenge existing paradigms. JID Innovations invites submission of original scientific articles, clinical trial reports, case reports and case series, descriptions of methods and new technologies, reviews, and letters to the Editor. The scope of JID Innovations is by design broad. As our subtitle - "Skin science from molecules to population health" - suggests, we will publish articles on all aspects of skin biology and pathology. We are interested in molecular mechanisms and population health. We will be soliciting review articles with a focus on what experiments need to be done, looking forward, not back. We will be interested both in studies that close knowledge gaps and those that expose gaps in our current thinking. We will also seek descriptions of new methods that have great potential in the investigation of skin and skin diseases. We will pursue studies that stimulate and guide future studies; molecular studies that suggest new therapeutic interventions; as well as small clinical trials that provide potentially critical clues for mechanisms of disease. So-called negative studies that address important questions and are well done are important in formulating future hypotheses, and they are welcome. Clinical trials on small, localized populations help researchers move towards larger definitive trials more quickly; JID Innovations welcomes these submissions as well. Well-done studies that contradict current dogma can open the scientific community's eyes to new paradigms, and these are also welcome. JID Innovations is committed to the principle that timely, barrier-free circulation of ideas is the best way to advance understanding.

Catalog source: scimago. This is not a copy of the publisher's author instructions.

Submission & timeline

Average review time
Information not currently available.
Acceptance rate
Information not currently available.
Article types accepted
Information not currently available.
Publication frequency
Information not currently available.

General pre-submission checks for medical manuscripts

Generic checklist only — not journal-specific requirements.

  • Confirm scope fit and intended article type on the official journal site.
  • Abstract structure matches the journal's current requirements.
  • Ethics approval and trial registration statements are complete.
  • Informed consent and patient privacy statements are in place.
  • Reporting guideline compliance (e.g. CONSORT, STROBE, PRISMA) as applicable.
  • Reference style and citation limits per official guidelines.
  • Figures and tables meet resolution, labeling, and count limits.
  • Cover letter addresses novelty, fit, and required declarations.
  • Conflicts of interest statement included.
  • Funding statement included.
  • Data availability statement included when required.

FAQ